,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['t-dxd']
with a significant expansion of the population where t-dxd will be indicated counselling &amp; monitoring for &amp; managing of ildpneumonitis will be key. these data are a little worrisome. education &amp; working with colleagues to ensure optimal care will be key #asco2022 
Professor of Translational Oncology and Consultant Medical Oncologist